Insmed (NASDAQ:INSM) Upgraded to "Overweight" at Morgan Stanley

Key Points

• Morgan Stanley upgraded Insmed from "equal weight" to Overweight and set a $212 price objective, implying about a 45.9% upside from the current share price.
• Analysts remain generally positive (consensus "Buy", average target ~$212.38), but Insmed recently missed EPS—reporting ($1.54) vs. ($1.07) expected—while revenue was roughly in line and rose 152.6% year‑over‑year despite continued negative margins and ROE.
• Insiders have been net sellers (CEO sold 19,215 shares and another insider sold 87,290 shares; 189,651 shares sold in the last 90 days), even as some institutions like HSBC and Rockefeller materially increased stakes.

Insmed (NASDAQ:INSM - Get Free Report) was upgraded by Morgan Stanley from an "equal weight" rating to an "overweight" rating in a report released on Monday, Marketbeat.com reports. The brokerage currently has a $212.00 price objective on the biopharmaceutical company's stock. Morgan Stanley's target price would indicate a potential upside of 45.91% from the stock's current price.

A number of other research firms have also commented on INSM. Truist Financial set a $205.00 price target on Insmed in a research report on Monday, January 12th. Wolfe Research set a $167.00 target price on Insmed and gave the company an "outperform" rating in a report on Thursday, December 18th. HC Wainwright raised their price target on Insmed from $230.00 to $245.00 and gave the stock a "buy" rating in a research note on Thursday. UBS Group cut their price target on shares of Insmed from $223.00 to $215.00 and set a "buy" rating on the stock in a report on Tuesday, January 6th. Finally, Citigroup reissued an "outperform" rating on shares of Insmed in a research report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Insmed presently has a consensus rating of "Buy" and an average price target of $212.38.

Insmed Stock Performance

NASDAQ:INSM opened at $145.30 on Monday. The firm has a market capitalization of $31.32 billion, a P/E ratio of -22.67 and a beta of 1.13. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. The company has a fifty day moving average of $150.13 and a 200 day moving average of $166.24. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed's revenue was up 152.6% on a year-over-year basis. During the same period last year, the business earned ($1.32) EPS. On average, research analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the transaction, the insider owned 41,754 shares of the company's stock, valued at approximately $7,315,300.80. This trade represents a 67.64% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 189,651 shares of company stock valued at $31,533,654. 3.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of INSM. Hsbc Holdings PLC boosted its stake in Insmed by 8,052.6% during the fourth quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company's stock worth $21,493,000 after acquiring an additional 121,755 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of Insmed by 88.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company's stock valued at $2,920,000 after purchasing an additional 7,863 shares during the last quarter. Corient Private Wealth LLC boosted its position in shares of Insmed by 34.1% in the 4th quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company's stock worth $3,631,000 after purchasing an additional 5,305 shares in the last quarter. Keenan LLC bought a new stake in shares of Insmed in the 4th quarter worth approximately $369,000. Finally, Reflection Asset Management purchased a new stake in shares of Insmed in the 4th quarter worth approximately $30,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.